Shizuka Seino
Yamagata, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Gemcitabine radiosensitization primes irradiated malignant meningioma cells for senolytic elimination by navitoclax.
Journal: Neuro-oncology advances
Published: November 12, 2021
Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction.
Journal: Life (Basel, Switzerland)
Published: July 15, 2021
Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
Journal: Anticancer research
Published: May 31, 2021
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Journal: Neuro-oncology
Published: February 08, 2021
Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1-JNK axis.
Journal: The Journal of biological chemistry
Published: July 14, 2020
Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway.
Journal: Anticancer research
Published: June 17, 2020
Doxazosin, a Classic Alpha 1-Adrenoceptor Antagonist, Overcomes Osimertinib Resistance in Cancer Cells via the Upregulation of Autophagy as Drug Repurposing.
Journal: Biomedicines
Published: June 16, 2020
Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs.
Journal: Cancers
Published: August 26, 2019
Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction.
Journal: Cancers
Published: May 29, 2019
In vitro and in vivo anti-tumor effects of brexpiprazole, a newly-developed serotonin-dopamine activity modulator with an improved safety profile.
Journal: Oncotarget
Published: February 25, 2019
Last Updated: 09/26/2026